Individual therapy: New dawn or false dawn?

Drug Information Journal

Volumn 35, Issue 4, 2001, Pages 1479-1494

  Senn, Stephen ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cross over trials; Effect sizes; n of 1 trials; Patient by treatment interaction

Indexed keywords

ARTICLE; CLINICAL RESEARCH; INDIVIDUALIZATION; PRIORITY JOURNAL; PROBABILITY; STATISTICAL ANALYSIS;

EID: 0035739148     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150103500443     Document Type: Article

References (44)

1. Pharmacogenomics: Translating functional genomics into rational therapeutics
2. Locally most powerful tests for detecting treatment effects when only a subset of patients can be expected to respond to treatment
3. Modelling of individual pharmacokinetics for computer-aided drug dosage
4. Introduction and overview
5. Can treatment that is helpful on average be harmful to some patients? A study of the conflicting information needs of clinical inquiry and drug regulation
6. Testing for qualitative interactions between treatment effects and patient subsets
7. On wisdom after the event
8. On subgroups and groping for significance
9. On reaching the tunnel at the end of the light
10. Graphical display of estimates having differing standard errors
11. A note on graphical presentation of estimated odds ratios from several clinical-trials
12. Some applications of radial plots
13. A likelihood approach to meta-analysis with random effects
14. Interpreting treatment effects in randomised trials
15. Numbers needed to treat: Properties and problems
16. Numbers needed to treat derived from meta-analyses-sometimes informative, usually misleading
17. Applying results of randomised trials to patients. N of 1 trials are needed
18. Quality-of-life assessment - Can we keep it simple
19. n of 1 trials comparing a non-steroidal anti-inflammatory drug with paracetamol in osteoarthritis
20. Suspended judgment n-of-1 trials
21. n of 1 trials in osteoarthritis. Caution in interpretation needed
22. The phenytoin trial is a case study of "individual bioequivalence."
23. Statistical method for demonstrating equivalence in crossover trials based on the ratio of two location parameters
24. In the blood: Proposed new requirements for registering generic drugs
25. Drug-grapefruit juice interactions
26. Hypothesis: Comparisons of inter- and intra-individual variations can substitute for twin studies in drug research
27. The science of pharmacological variability: An essay
28. Evaluation of the genetic component of variability in CYP3A4 activity: A repeated drug administration method
29. Crossover Design
30. Cross-over trials
31. Gender representation in trials
32. Testing for individual and population equivalence based on the proportion of similar responses
33. Testing for individual and population equivalence based on the proportion of similar responses
34. Generalized treatment effects for clinical trials
35. A nonparametric procedure associated with a clinically meaningful efficacy measure
36. Primary, secondary and meta-analysis of research
37. The central role of the propensity score in observational studies for causal effect
38. Estimating causal effects of treatment in randomized and nonrandomized studies
39. Pharmacogenetics and adverse drug reactions
40. Evidence of a major gene effect for angiotensinogen among Nigerians